You are here: Industry Insights > financial results

News List

AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results americanpharmaceuticalreview
January 29, 2018
2017 reflects another year of top-tier performance, demonstrating the strong momentum in our business," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie
VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update prnasia
November 10, 2017
VolitionRx Limited (NYSE American: VNRX) today announced financial results and a business update for the third quarter ended September 30, 2017.
Darling Ingredients Inc. Reports Third Quarter 2017 Financial Results prnasia
November 08, 2017
For the third quarter of 2017, the Company reported net sales of $937.7 million, as compared with net sales of $853.9 million for the third quarter of 2016.
China Biologic Reports Unaudited Financial Results for the Third Quarter of 2017 prnasia
November 02, 2017
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the third quarter of 2017.
Suven’s revenue declines by 21 per cent expressbpd
August 17, 2017
PAT was registered at Rs 295 million against Rs 403 million
Suven’s revenue declines by 21 per cent expressbpd
August 16, 2017
PAT was registered at Rs 295 million against Rs 403 million
Biohaven Reports Second Quarter 2017 Results americanpharmaceuticalreview
August 15, 2017
Biohaven Pharmaceutical reported financial results for the quarter ended June 30, 2017.
China Biologic Products to Report Second Quarter of 2017 Financial Results en-cphi.cn
July 20, 2017
China Biologic Products, Inc. (NASDAQ: CBPO) (China Biologic or the Company), a leading fully integrated plasma-based bi
China Pharma Holdings, Inc. Reports First Quarter 2017 Financial Results en-cphi.cn
May 15, 2017
China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma," the "Company" or "We"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended Ma
Dr Reddy’s posts Q4 and FY17 financial results financialexpress
May 15, 2017
In FY17, revenues were at Rs 140.8 billion and EBITDA at Rs 25.5 billion

Previous page 1 2 3 4 5 6 Next page